Patient characteristics and treatment
| ID . | Sex . | Age at diagnosis (y) . | Associated myeloid disorder . | Mutations (VAF%) . | IPI at diagnosis . | Number of previous therapies . | Previous auto-HSCT . | Stage . | LDH . | ECOG . | Rituximab (no. of cycles) . | 5-azacytidine (no. of cycles) . | Best response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCL1 | F | 79 | CMML | TET2 p.Q891fs (34.6) | 4 | 0 | 0 | 3 | 1 | 2 | 4 | 61 | CR |
| TET2 c.3955-2A>G (38.4) | |||||||||||||
| PTCL2 | M | 69 | MDS | TET2 p.I249fs (30) | 3 | 1 | 0 | 4 | 0 | 2 | 4 | 25 | CR |
| PTCL3 | F | 70 | No | TET2 p.C1271W (82) | 2 | 6 | 0 | 3 | 0 | 1 | 0 | 7 | CR |
| RHOA p.K18N (11.4) | |||||||||||||
| PTCL4 | M | 75 | CMML | TET2 p.E1879A (23) | 2 | 4 | 0 | 3 | 1 | 3 | 0 | 6 | CR |
| PTCL5 | M | 63 | No | TET2 p.H1904R (42.2) | 4 | 2 | 1 | 4 | 1 | 1 | 6 | 5 | CR |
| TET2 p.E1207K (44) | |||||||||||||
| DNMT3A p.G707fs (40.20%) | |||||||||||||
| PTCL6 | F | 73 | No | TET2 p.R1465X (28.3) | 4 | 2 | 0 | 4 | 1 | 4 | 8 | 16 | PR |
| DNMT3A p.R882H (30.6) | |||||||||||||
| RHOA p.G17V (24.3) | |||||||||||||
| PTCL7 | F | 85 | CMML | TET2 p.S835X (27.6) | 3 | 1 | 0 | 4 | 0 | 4 | 0 | 20 | CR |
| TET2 c.3594+1G>C (24.7) | |||||||||||||
| DNMT3A p.R882H (27) | |||||||||||||
| RHOA p.G17V (2.8) | |||||||||||||
| PTCL8 | M | 39 | No | TET2 p.T938fs (30.3) | 4 | 2 | 0 | 4 | 1 | 1 | 6 | 4 | SD |
| RHOA p.G17V (29.10) | |||||||||||||
| PTCL9 | F | 81 | CMML | TET2 p.R1404X (30) | 3 | 3 | 0 | 4 | 1 | 1 | 0 | 4 | PR |
| TET2 p.C1298Y (31) | |||||||||||||
| RHOA p.G17V (12.10) | |||||||||||||
| PTCL10 | M | 51 | No | TET2 p.R1216X (11.3) | 2 | 3 | 1 | 3 | 1 | 1 | 0 | 3 | PR |
| TET2 p.C1271W (8.9) | |||||||||||||
| IDH2 p.R172K (2.2) | |||||||||||||
| PTCL11 | M | 71 | No | TET2 p.H1904L (24.8) | 5 | 2 | 0 | 4 | 1 | 2 | 6 | 2 | SD |
| DNMT3A p.R882H (45.3) | |||||||||||||
| PTCL12 | M | 69 | No | TET2 p.L1244fs (28.3) | 5 | 2 | 0 | 4 | 1 | 4 | 0 | 2 | SD |
| TET2 p.H937fs (10.2) |
| ID . | Sex . | Age at diagnosis (y) . | Associated myeloid disorder . | Mutations (VAF%) . | IPI at diagnosis . | Number of previous therapies . | Previous auto-HSCT . | Stage . | LDH . | ECOG . | Rituximab (no. of cycles) . | 5-azacytidine (no. of cycles) . | Best response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCL1 | F | 79 | CMML | TET2 p.Q891fs (34.6) | 4 | 0 | 0 | 3 | 1 | 2 | 4 | 61 | CR |
| TET2 c.3955-2A>G (38.4) | |||||||||||||
| PTCL2 | M | 69 | MDS | TET2 p.I249fs (30) | 3 | 1 | 0 | 4 | 0 | 2 | 4 | 25 | CR |
| PTCL3 | F | 70 | No | TET2 p.C1271W (82) | 2 | 6 | 0 | 3 | 0 | 1 | 0 | 7 | CR |
| RHOA p.K18N (11.4) | |||||||||||||
| PTCL4 | M | 75 | CMML | TET2 p.E1879A (23) | 2 | 4 | 0 | 3 | 1 | 3 | 0 | 6 | CR |
| PTCL5 | M | 63 | No | TET2 p.H1904R (42.2) | 4 | 2 | 1 | 4 | 1 | 1 | 6 | 5 | CR |
| TET2 p.E1207K (44) | |||||||||||||
| DNMT3A p.G707fs (40.20%) | |||||||||||||
| PTCL6 | F | 73 | No | TET2 p.R1465X (28.3) | 4 | 2 | 0 | 4 | 1 | 4 | 8 | 16 | PR |
| DNMT3A p.R882H (30.6) | |||||||||||||
| RHOA p.G17V (24.3) | |||||||||||||
| PTCL7 | F | 85 | CMML | TET2 p.S835X (27.6) | 3 | 1 | 0 | 4 | 0 | 4 | 0 | 20 | CR |
| TET2 c.3594+1G>C (24.7) | |||||||||||||
| DNMT3A p.R882H (27) | |||||||||||||
| RHOA p.G17V (2.8) | |||||||||||||
| PTCL8 | M | 39 | No | TET2 p.T938fs (30.3) | 4 | 2 | 0 | 4 | 1 | 1 | 6 | 4 | SD |
| RHOA p.G17V (29.10) | |||||||||||||
| PTCL9 | F | 81 | CMML | TET2 p.R1404X (30) | 3 | 3 | 0 | 4 | 1 | 1 | 0 | 4 | PR |
| TET2 p.C1298Y (31) | |||||||||||||
| RHOA p.G17V (12.10) | |||||||||||||
| PTCL10 | M | 51 | No | TET2 p.R1216X (11.3) | 2 | 3 | 1 | 3 | 1 | 1 | 0 | 3 | PR |
| TET2 p.C1271W (8.9) | |||||||||||||
| IDH2 p.R172K (2.2) | |||||||||||||
| PTCL11 | M | 71 | No | TET2 p.H1904L (24.8) | 5 | 2 | 0 | 4 | 1 | 2 | 6 | 2 | SD |
| DNMT3A p.R882H (45.3) | |||||||||||||
| PTCL12 | M | 69 | No | TET2 p.L1244fs (28.3) | 5 | 2 | 0 | 4 | 1 | 4 | 0 | 2 | SD |
| TET2 p.H937fs (10.2) |
F, female; HSCT, hematopoietic stem cell transplant; IPI, International Prognostic Index; M, male, MDS, myelodysplastic syndrome; SD, stable disease; VAF, variant allele frequency.